{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:12:12Z","timestamp":1770999132449,"version":"3.50.1"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,5]],"date-time":"2012-02-05T00:00:00Z","timestamp":1328400000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s12016-012-8301-7","type":"journal-article","created":{"date-parts":[[2012,2,4]],"date-time":"2012-02-04T14:03:11Z","timestamp":1328364191000},"page":"121-140","source":"Crossref","is-referenced-by-count":61,"title":["Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring"],"prefix":"10.1007","volume":"44","author":[{"given":"Raja K.","family":"Sivamani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki Shirakawa","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa N.","family":"Wehrli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanual","family":"Maverakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,5]]},"reference":[{"key":"8301_CR1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","volume":"26","author":"E Christophers","year":"2001","unstructured":"Christophers E (2001) Psoriasis\u2014epidemiology and clinical spectrum. Clin Exp Dermatol 26:314\u2013320","journal-title":"Clin Exp Dermatol"},{"key":"8301_CR2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","volume":"141","author":"DM Ashcroft","year":"1999","unstructured":"Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141:185\u2013191","journal-title":"Br J Dermatol"},{"key":"8301_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00128071-200304070-00001","volume":"4","author":"H Zachariae","year":"2003","unstructured":"Zachariae H (2003) Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4:441\u2013447","journal-title":"Am J Clin Dermatol"},{"key":"8301_CR4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ng.694","volume":"42","author":"A Strange","year":"2010","unstructured":"Strange A et al (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42:985\u2013U106","journal-title":"Nat Genet"},{"key":"8301_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2004.03.006","volume":"25","author":"W Lew","year":"2004","unstructured":"Lew W, Bowcock AM, Krueger JG (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and \u201cType 1\u201d inflammatory gene expression. Trends Immunol 25:295\u2013305","journal-title":"Trends Immunol"},{"key":"8301_CR6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496\u2013509","journal-title":"N Engl J Med"},{"key":"8301_CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1523-1747.ep12371752","volume":"102","author":"JF Schlaak","year":"1994","unstructured":"Schlaak JF et al (1994) T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102:145\u2013149","journal-title":"J Invest Dermatol"},{"key":"8301_CR8","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","volume":"204","author":"LC Zaba","year":"2007","unstructured":"Zaba LC et al (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204:3183\u20133194","journal-title":"J Exp Med"},{"key":"8301_CR9","doi-asserted-by":"crossref","first-page":"e14108","DOI":"10.1371\/journal.pone.0014108","volume":"5","author":"PC Res","year":"2010","unstructured":"Res PC et al (2010) Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5:e14108","journal-title":"PLoS One"},{"key":"8301_CR10","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2010-01-263509","volume":"116","author":"C Schirmer","year":"2010","unstructured":"Schirmer C, Klein C, von Bergen M, Simon JC, Saalbach A (2010) Human fibroblasts support the expansion of IL-17-producing T cells via up-regulation of IL-23 production by dendritic cells. Blood 116:1715\u20131725","journal-title":"Blood"},{"key":"8301_CR11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","volume":"467","author":"K Ghoreschi","year":"2010","unstructured":"Ghoreschi K et al (2010) Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467:967\u2013U144","journal-title":"Nature"},{"key":"8301_CR12","doi-asserted-by":"crossref","unstructured":"Wolk K et al (2009) The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39:3570\u20133581","DOI":"10.1002\/eji.200939687"},{"key":"8301_CR13","first-page":"1092","volume":"159","author":"KE Nograles","year":"2008","unstructured":"Nograles KE et al (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159:1092\u20131102","journal-title":"Br J Dermatol"},{"key":"8301_CR14","first-page":"597","volume":"118","author":"HL Ma","year":"2008","unstructured":"Ma HL et al (2008) IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118:597\u2013607","journal-title":"J Clin Invest"},{"key":"8301_CR15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.det.2004.03.011","volume":"22","author":"L Winterfield","year":"2004","unstructured":"Winterfield L, Menter A (2004) Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin 22:437\u2013447, ix","journal-title":"Dermatol Clin"},{"key":"8301_CR16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.200535503","volume":"36","author":"K Wolk","year":"2006","unstructured":"Wolk K et al (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36:1309\u20131323","journal-title":"Eur J Immunol"},{"key":"8301_CR17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","volume":"445","author":"Y Zheng","year":"2007","unstructured":"Zheng Y et al (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648\u2013651","journal-title":"Nature"},{"key":"8301_CR18","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nm.1995","volume":"15","author":"R Caruso","year":"2009","unstructured":"Caruso R et al (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013\u20131015","journal-title":"Nat Med"},{"key":"8301_CR19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2340\/0001555559441445","volume":"59","author":"A Wahba","year":"1979","unstructured":"Wahba A, Cohen H, Bareli M, Callily R (1979) Neutrophil chemotaxis in psoriasis. Acta Derm Venereol 59:441\u2013445","journal-title":"Acta Derm Venereol"},{"key":"8301_CR20","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1073\/pnas.1000803107","volume":"107","author":"TC Theoharides","year":"2010","unstructured":"Theoharides TC et al (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107:4448\u20134453","journal-title":"Proc Natl Acad Sci USA"},{"key":"8301_CR21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2133.2006.07405.x","volume":"155","author":"L Dubertret","year":"2006","unstructured":"Dubertret L et al (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155:729\u2013736","journal-title":"Br J Dermatol"},{"key":"8301_CR22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaad.2004.10.862","volume":"52","author":"T Nijsten","year":"2005","unstructured":"Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS (2005) Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 52:434\u2013444","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.autrev.2009.12.010","volume":"9","author":"R Caporali","year":"2010","unstructured":"Caporali R et al (2010) Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 9:465\u2013469","journal-title":"Autoimmun Rev"},{"key":"8301_CR24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jbspin.2007.10.001","volume":"74","author":"B Fautrel","year":"2007","unstructured":"Fautrel B et al (2007) Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 74:627\u2013637","journal-title":"Joint Bone Spine"},{"key":"8301_CR25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/rheumatology\/keq008","volume":"49","author":"A Spadaro","year":"2010","unstructured":"Spadaro A et al (2010) Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology 49:1107\u20131111","journal-title":"Rheumatology"},{"key":"8301_CR26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000113943","volume":"216","author":"G Pitarch","year":"2008","unstructured":"Pitarch G, Sanchez-Carazo JL, Mahiques L, Oliver V (2008) Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 216:312\u2013316","journal-title":"Dermatology"},{"key":"8301_CR27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","volume":"70","author":"A Jamnitski","year":"2011","unstructured":"Jamnitski A et al (2011) The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70:284\u2013288","journal-title":"Ann Rheum Dis"},{"key":"8301_CR28","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti F et al (2007) Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 66:1393\u20131397","journal-title":"Ann Rheum Dis"},{"key":"8301_CR29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418\u2013426","journal-title":"J Pharmacol Exp Ther"},{"key":"8301_CR30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.60.7.660","volume":"60","author":"P Barrera","year":"2001","unstructured":"Barrera P et al (2001) Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 60:660\u2013669","journal-title":"Ann Rheum Dis"},{"key":"8301_CR31","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"P Charles","year":"1999","unstructured":"Charles P et al (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163:1521\u20131528","journal-title":"J Immunol"},{"key":"8301_CR32","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.4049\/jimmunol.155.10.5038","volume":"155","author":"AF Suffredini","year":"1995","unstructured":"Suffredini AF et al (1995) Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038\u20135045","journal-title":"J Immunol"},{"key":"8301_CR33","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645\u20132668","journal-title":"J Pharm Sci"},{"key":"8301_CR34","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.4049\/jimmunol.149.12.3881","volume":"149","author":"CF Ware","year":"1992","unstructured":"Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL (1992) Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149:3881\u20133888","journal-title":"J Immunol"},{"key":"8301_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/abio.2001.5380","volume":"299","author":"LC Santora","year":"2001","unstructured":"Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K (2001) Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299:119\u2013129","journal-title":"Anal Biochem"},{"key":"8301_CR36","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.164.12.6193","volume":"164","author":"G Eissner","year":"2000","unstructured":"Eissner G et al (2000) Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 164:6193\u20136198","journal-title":"J Immunol"},{"key":"8301_CR37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cyto.2004.06.008","volume":"28","author":"S Kirchner","year":"2004","unstructured":"Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G (2004) Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28:67\u201374","journal-title":"Cytokine"},{"key":"8301_CR38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2036.2005.02309.x","volume":"21","author":"C Shen","year":"2005","unstructured":"Shen C et al (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21:251\u2013258","journal-title":"Aliment Pharmacol Ther"},{"key":"8301_CR39","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1053\/j.gastro.2004.01.036","volume":"126","author":"H Mitoma","year":"2004","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H (2004) Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 126:934\u2013935, author reply 935\u2013936","journal-title":"Gastroenterology"},{"key":"8301_CR40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cyto.2008.11.008","volume":"45","author":"T Arora","year":"2009","unstructured":"Arora T et al (2009) Differences in binding and effector functions between classes of TNF antagonists. Cytokine 45:124\u2013131","journal-title":"Cytokine"},{"key":"8301_CR41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","volume":"131","author":"Z Kaymakcalan","year":"2009","unstructured":"Kaymakcalan Z et al (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131:308\u2013316","journal-title":"Clin Immunol"},{"key":"8301_CR42","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"JM Brande Van den","year":"2003","unstructured":"Van den Brande JM et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology 124:1774\u20131785","journal-title":"Gastroenterology"},{"key":"8301_CR43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","volume":"50","author":"T Hove ten","year":"2002","unstructured":"ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ (2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease. Gut 50:206\u2013211","journal-title":"Gut"},{"key":"8301_CR44","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","volume":"121","author":"A Lugering","year":"2001","unstructured":"Lugering A et al (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway. Gastroenterology 121:1145\u20131157","journal-title":"Gastroenterology"},{"key":"8301_CR45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","volume":"34","author":"I Nestorov","year":"2005","unstructured":"Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34:12\u201318","journal-title":"Semin Arthritis Rheum"},{"key":"8301_CR46","first-page":"13","volume":"74","author":"I Nestorov","year":"2005","unstructured":"Nestorov I (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74:13\u201318","journal-title":"J Rheumatol Suppl"},{"key":"8301_CR47","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","volume":"46","author":"EW St Clair","year":"2002","unstructured":"St Clair EW et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1451\u20131459","journal-title":"Arthritis Rheum"},{"key":"8301_CR48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-008-9233-0","volume":"29","author":"M Caproni","year":"2009","unstructured":"Caproni M et al (2009) Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29:210\u2013214","journal-title":"J Clin Immunol"},{"issue":"1022\u20131010","key":"8301_CR49","first-page":"e1021","volume":"124","author":"LC Zaba","year":"2009","unstructured":"Zaba LC et al (2009) Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124(1022\u20131010):e1021\u2013e1395","journal-title":"J Allergy Clin Immunol"},{"key":"8301_CR50","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2310\/JIM.0b013e3181eb9895","volume":"58","author":"H Shen","year":"2010","unstructured":"Shen H, Xia L, Lu J, Xiao W (2010) Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Investig Med 58:905\u2013908","journal-title":"J Investig Med"},{"key":"8301_CR51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10067-006-0312-4","volume":"26","author":"Y Kageyama","year":"2007","unstructured":"Kageyama Y et al (2007) Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 26:505\u2013509","journal-title":"Clin Rheumatol"},{"key":"8301_CR52","first-page":"118","volume":"22","author":"S Gudbrandsdottir","year":"2004","unstructured":"Gudbrandsdottir S et al (2004) TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 22:118\u2013124","journal-title":"Clin Exp Rheumatol"},{"key":"8301_CR53","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.8171323","volume":"264","author":"PD Crowe","year":"1994","unstructured":"Crowe PD et al (1994) A lymphotoxin-beta-specific receptor. Science 264:707\u2013710","journal-title":"Science"},{"key":"8301_CR54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev.immunol.23.021704.115719","volume":"23","author":"CF Ware","year":"2005","unstructured":"Ware CF (2005) Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23:787\u2013819","journal-title":"Annu Rev Immunol"},{"key":"8301_CR55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4049\/jimmunol.154.1.33","volume":"154","author":"JL Browning","year":"1995","unstructured":"Browning JL et al (1995) Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J Immunol 154:33\u201346","journal-title":"J Immunol"},{"key":"8301_CR56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/326304a0","volume":"326","author":"R Pujol-Borrell","year":"1987","unstructured":"Pujol-Borrell R et al (1987) HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 326:304\u2013306","journal-title":"Nature"},{"key":"8301_CR57","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","volume":"203","author":"JR Chan","year":"2006","unstructured":"Chan JR et al (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203:2577\u20132587","journal-title":"J Exp Med"},{"key":"8301_CR58","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","volume":"194","author":"P Ye","year":"2001","unstructured":"Ye P et al (2001) Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194:519\u2013527","journal-title":"J Exp Med"},{"key":"8301_CR59","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","volume":"345","author":"CN Ellis","year":"2001","unstructured":"Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248\u2013255","journal-title":"N Engl J Med"},{"key":"8301_CR60","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mjd.2002.127247","volume":"47","author":"GG Krueger","year":"2002","unstructured":"Krueger GG et al (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47:821\u2013833","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","volume":"139","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M et al (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719\u2013727","journal-title":"Arch Dermatol"},{"key":"8301_CR62","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2008.08673.x","volume":"159","author":"AK Brimhall","year":"2008","unstructured":"Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A (2008) Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 159:274\u2013285","journal-title":"Br J Dermatol"},{"issue":"31","key":"8301_CR63","first-page":"e31","volume":"56","author":"A Menter","year":"2007","unstructured":"Menter A et al (2007) A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1\u00a0year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56(31):e31\u2013e15","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR64","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB et al (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51:534\u2013542","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR65","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367\u20131374","journal-title":"Lancet"},{"key":"8301_CR66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","volume":"36","author":"WYK Hwang","year":"2005","unstructured":"Hwang WYK, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3\u201310","journal-title":"Methods"},{"key":"8301_CR67","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552\u20131563","journal-title":"Arthritis Rheum"},{"key":"8301_CR68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","volume":"34","author":"PJ Anderson","year":"2005","unstructured":"Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34:19\u201322","journal-title":"Semin Arthritis Rheum"},{"key":"8301_CR69","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K et al (2006) Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 54:3782\u20133789","journal-title":"Arthritis Rheum"},{"key":"8301_CR70","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 348:601\u2013608","journal-title":"N Engl J Med"},{"key":"8301_CR71","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","volume":"143","author":"S Tyring","year":"2007","unstructured":"Tyring S et al (2007) Long-term safety and efficacy of 50\u00a0mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143:719\u2013726","journal-title":"Arch Dermatol"},{"key":"8301_CR72","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","volume":"152","author":"KA Papp","year":"2005","unstructured":"Papp KA et al (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152:1304\u20131312","journal-title":"Br J Dermatol"},{"key":"8301_CR73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","volume":"358","author":"AS Paller","year":"2008","unstructured":"Paller AS et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358:241\u2013251","journal-title":"N Engl J Med"},{"key":"8301_CR74","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349","author":"CL Leonardi","year":"2003","unstructured":"Leonardi CL et al (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014\u20132022","journal-title":"N Engl J Med"},{"key":"8301_CR75","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","volume":"139","author":"AB Gottlieb","year":"2003","unstructured":"Gottlieb AB et al (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627\u20131632, discussion 1632","journal-title":"Arch Dermatol"},{"key":"8301_CR76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2340\/00015555-0511","volume":"88","author":"C Zachariae","year":"2008","unstructured":"Zachariae C et al (2008) The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 88:495\u2013501","journal-title":"Acta Derm Venereol"},{"key":"8301_CR77","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon KB et al (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55:598\u2013606","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR78","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","volume":"158","author":"JH Saurat","year":"2008","unstructured":"Saurat JH et al (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158:558\u2013566","journal-title":"Br J Dermatol"},{"key":"8301_CR79","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A et al (2008) Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58:106\u2013115","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR80","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976\u2013986","journal-title":"Arthritis Rheum"},{"key":"8301_CR81","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675\u20131684","journal-title":"Lancet"},{"key":"8301_CR82","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665\u20131674","journal-title":"Lancet"},{"key":"8301_CR83","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","volume":"144","author":"AB Kimball","year":"2008","unstructured":"Kimball AB et al (2008) Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 144:200\u2013207","journal-title":"Arch Dermatol"},{"key":"8301_CR84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaad.2010.01.030","volume":"64","author":"AB Kimball","year":"2011","unstructured":"Kimball AB et al (2011) Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12\/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation\/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol 64:263\u2013274","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR85","unstructured":"Anonymous (Released on October 11, 2010) http:\/\/www.abbott.com\/global\/url\/pressRelease\/en_US\/Press_Release_0909.htm , Abbot Reports Psoriasis Phase III Results of its Investigational IL-12\/23 Inhibitor Briakinumab (ABT-874). Last accessed on January 23, 2011"},{"key":"8301_CR86","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"P Mease","year":"2011","unstructured":"Mease P et al (2011) Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 63:939\u2013948","journal-title":"Arthritis Rheum"},{"key":"8301_CR87","unstructured":"www.clinicaltrials.gov . Accessed 25 Nov 2011"},{"key":"8301_CR88","first-page":"117","volume":"88","author":"D Silverman","year":"2011","unstructured":"Silverman D, Oliver A (2011) Abatacept-induced psoriasis. Cutis 88:117\u2013118","journal-title":"Cutis"},{"key":"8301_CR89","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2340\/00015555-1042","volume":"91","author":"K Kato","year":"2011","unstructured":"Kato K, Satoh T, Nishizawa A, Yokozeki H (2011) Psoriasiform drug eruption due to abatacept. Acta Derm Venereol 91:362\u2013363","journal-title":"Acta Derm Venereol"},{"key":"8301_CR90","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"W Hueber","year":"2010","unstructured":"Hueber W et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72","journal-title":"Sci Transl Med"},{"key":"8301_CR91","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1365-2133.2004.05960.x","volume":"150","author":"S Benoit","year":"2004","unstructured":"Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M (2004) Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 150:1009\u20131012","journal-title":"Br J Dermatol"},{"key":"8301_CR92","first-page":"71","volume":"18","author":"V Vieira Serrao","year":"2008","unstructured":"Vieira Serrao V, Martins A, Lopes MJ (2008) Infliximab in recalcitrant generalized pustular arthropatic psoriasis. Eur J Dermatol 18:71\u201373","journal-title":"Eur J Dermatol"},{"key":"8301_CR93","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000277415","volume":"220","author":"L Puig","year":"2010","unstructured":"Puig L, Barco D, Vilarrasa E, Alomar A (2010) Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review. Dermatology 220:154\u2013158","journal-title":"Dermatology"},{"key":"8301_CR94","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2133.2006.07217.x","volume":"155","author":"M Esposito","year":"2006","unstructured":"Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S (2006) Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 155:156\u2013159","journal-title":"Br J Dermatol"},{"key":"8301_CR95","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard.2003.014191","volume":"63","author":"C Fiehn","year":"2004","unstructured":"Fiehn C, Andrassy K (2004) Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis 63:232","journal-title":"Ann Rheum Dis"},{"key":"8301_CR96","first-page":"247","volume":"84","author":"S Lisby","year":"2004","unstructured":"Lisby S, Gniadecki R (2004) Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol 84:247\u2013248","journal-title":"Acta Derm Venereol"},{"key":"8301_CR97","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2133.2007.08111.x","volume":"157","author":"MD Takahashi","year":"2007","unstructured":"Takahashi MD, Castro LG, Romiti R (2007) Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol 157:828\u2013831","journal-title":"Br J Dermatol"},{"key":"8301_CR98","first-page":"940","volume":"7","author":"R Bissonnette","year":"2008","unstructured":"Bissonnette R et al (2008) Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 7:940\u2013946","journal-title":"J Drugs Dermatol"},{"key":"8301_CR99","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/BOR.0b013e32833a3d42","volume":"22","author":"L Harty","year":"2010","unstructured":"Harty L, Veale DJ (2010) How early should psoriatic arthritis be treated with a TNF-blocker? Curr Opin Rheumatol 22:393\u2013396","journal-title":"Curr Opin Rheumatol"},{"key":"8301_CR100","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314\u2013J321","journal-title":"J Autoimmun"},{"key":"8301_CR101","doi-asserted-by":"crossref","unstructured":"Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA (2011) Efficacy and safety results from a phase III, randomised controlled trial comparing the safety and efficacy of briakinumab to etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165:661\u2013668","DOI":"10.1111\/j.1365-2133.2011.10419.x"},{"key":"8301_CR102","doi-asserted-by":"crossref","unstructured":"Gottlieb AB et al (2011) Efficacy and safety of briakinumab versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165:652\u2013660","DOI":"10.1111\/j.1365-2133.2011.10418.x"},{"key":"8301_CR103","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CE Griffiths","year":"2010","unstructured":"Griffiths CE et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118\u2013128","journal-title":"N Engl J Med"},{"key":"8301_CR104","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10067-009-1340-7","volume":"29","author":"M Atteno","year":"2010","unstructured":"Atteno M et al (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29:399\u2013403","journal-title":"Clin Rheumatol"},{"key":"8301_CR105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10399.x","volume":"165","author":"JH Saurat","year":"2011","unstructured":"Saurat JH et al (2011) Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol 165:399\u2013406","journal-title":"Br J Dermatol"},{"key":"8301_CR106","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2230.1982.tb02465.x","volume":"7","author":"L Hendel","year":"1982","unstructured":"Hendel L, Hendel J, Johnsen A, Gudmand-Hoyer E (1982) Intestinal function and methotrexate absorption in psoriatic patients. Clin Exp Dermatol 7:491\u2013497","journal-title":"Clin Exp Dermatol"},{"key":"8301_CR107","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2009.12.029","volume":"63","author":"K Reich","year":"2010","unstructured":"Reich K et al (2010) Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol 63:1011\u20131018","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR108","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/rheumatology\/ken190","volume":"47","author":"Y Yazici","year":"2008","unstructured":"Yazici Y, Adler NM, Yazici H (2008) Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called \u2018efficacy and safety\u2019 trials: a survey of power considerations. Rheumatology (Oxford) 47:1054\u20131057","journal-title":"Rheumatology (Oxford)"},{"key":"8301_CR109","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","volume":"138","author":"HJ Kwon","year":"2003","unstructured":"Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807\u2013811","journal-title":"Ann Intern Med"},{"key":"8301_CR110","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann DL et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594\u20131602","journal-title":"Circulation"},{"key":"8301_CR111","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","volume":"57","author":"NL Sicotte","year":"2001","unstructured":"Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57:1885\u20131888","journal-title":"Neurology"},{"key":"8301_CR112","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58:851\u2013864","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR113","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826\u2013850","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"U Wollina","year":"2008","unstructured":"Wollina U et al (2008) Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9:1\u201314","journal-title":"Am J Clin Dermatol"},{"key":"8301_CR115","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","volume":"59","author":"AN Collamer","year":"2008","unstructured":"Collamer AN, Guerrero KT, Henning JS, Battafarano DF (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 59:996\u20131001","journal-title":"Arthritis Rheum"},{"key":"8301_CR116","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242\u2013251","journal-title":"Medicine (Baltimore)"},{"key":"8301_CR117","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","volume":"68","author":"MJ Harrison","year":"2009","unstructured":"Harrison MJ et al (2009) Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 68:209\u2013215","journal-title":"Ann Rheum Dis"},{"key":"8301_CR118","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI117394","volume":"94","author":"AP Cope","year":"1994","unstructured":"Cope AP et al (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749\u2013760","journal-title":"J Clin Invest"},{"key":"8301_CR119","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1084\/jem.184.4.1397","volume":"184","author":"M Pasparakis","year":"1996","unstructured":"Pasparakis M, Alexopoulou L, Episkopou V, Kollias G (1996) Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184:1397\u20131411","journal-title":"J Exp Med"},{"issue":"Suppl 3","key":"8301_CR120","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1186\/ar570","volume":"4","author":"H McDevitt","year":"2002","unstructured":"McDevitt H, Munson S, Ettinger R, Wu A (2002) Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha\/beta in immunity and autoimmunity. Arthritis Res 4(Suppl 3):S141\u2013S152","journal-title":"Arthritis Res"},{"key":"8301_CR121","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/jaut.2000.0493","volume":"16","author":"E Maverakis","year":"2001","unstructured":"Maverakis E, van den Elzen P, Sercarz EE (2001) Self-reactive T cells and degeneracy of T cell recognition: evolving concepts\u2014from sequence homology to shape mimicry and TCR flexibility. J Autoimmun 16:201\u2013209","journal-title":"J Autoimmun"},{"key":"8301_CR122","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1073\/pnas.0936151100","volume":"100","author":"E Maverakis","year":"2003","unstructured":"Maverakis E et al (2003) Autoreactive T cells can be protected from tolerance induction through competition by flanking determinants for access to class II MHC. Proc Natl Acad Sci USA 100:5342\u20135347","journal-title":"Proc Natl Acad Sci USA"},{"key":"8301_CR123","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","volume":"52","author":"L Rycke De","year":"2005","unstructured":"De Rycke L et al (2005) Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52:2192\u20132201","journal-title":"Arthritis Rheum"},{"key":"8301_CR124","doi-asserted-by":"crossref","unstructured":"Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS (2011) The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol. doi: 10.1007\/s12016-010-8248-5","DOI":"10.1007\/s12016-010-8248-5"},{"key":"8301_CR125","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","volume":"13","author":"JR Rosh","year":"2007","unstructured":"Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn\u2019s disease: a cautionary tale? Inflamm Bowel Dis 13:1024\u20131030","journal-title":"Inflamm Bowel Dis"},{"key":"8301_CR126","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","volume":"46","author":"SL Brown","year":"2002","unstructured":"Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151\u20133158","journal-title":"Arthritis Rheum"},{"key":"8301_CR127","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56:2886\u20132895","journal-title":"Arthritis Rheum"},{"key":"8301_CR128","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275\u20132285","journal-title":"JAMA"},{"key":"8301_CR129","doi-asserted-by":"crossref","first-page":"J247","DOI":"10.1016\/j.jaut.2009.11.011","volume":"34","author":"E Maverakis","year":"2010","unstructured":"Maverakis E et al (2010) Light, including ultraviolet. J Autoimmun 34:J247\u2013J257","journal-title":"J Autoimmun"},{"key":"8301_CR130","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","volume":"60","author":"RV Patel","year":"2009","unstructured":"Patel RV, Clark LN, Lebwohl M, Weinberg JM (2009) Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 60:1001\u20131017","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR131","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","volume":"4","author":"EA Vasiliauskas","year":"2006","unstructured":"Vasiliauskas EA et al (2006) Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 4:1255\u20131258","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8301_CR132","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00054725-200608000-00020","volume":"12","author":"DS Mishkin","year":"2006","unstructured":"Mishkin DS, Van Deinse W, Becker JM, Farraye FA (2006) Successful use of adalimumab (Humira) for Crohn\u2019s disease in pregnancy. Inflamm Bowel Dis 12:827\u2013828","journal-title":"Inflamm Bowel Dis"},{"key":"8301_CR133","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/kel400","volume":"46","author":"CH Roux","year":"2007","unstructured":"Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2007) Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 46:695\u2013698","journal-title":"Rheumatology (Oxford)"},{"key":"8301_CR134","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s10620-006-9452-2","volume":"51","author":"LA Coburn","year":"2006","unstructured":"Coburn LA, Wise PE, Schwartz DA (2006) The successful use of adalimumab to treat active Crohn\u2019s disease of an ileoanal pouch during pregnancy. Dig Dis Sci 51:2045\u20132047","journal-title":"Dig Dis Sci"},{"key":"8301_CR135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","volume":"36","author":"JD Carter","year":"2009","unstructured":"Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36:635\u2013641","journal-title":"J Rheumatol"},{"key":"8301_CR136","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I et al (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36:1185\u20131206","journal-title":"Eur Respir J"},{"key":"8301_CR137","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-065X.2008.00702.x","volume":"226","author":"AM Cooper","year":"2008","unstructured":"Cooper AM, Khader SA (2008) The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 226:191\u2013204","journal-title":"Immunol Rev"},{"key":"8301_CR138","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","volume":"175","author":"SA Khader","year":"2005","unstructured":"Khader SA et al (2005) IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 175:788\u2013795","journal-title":"J Immunol"},{"key":"8301_CR139","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148\u2013155","journal-title":"Lancet Infect Dis"},{"key":"8301_CR140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2008.05.033","volume":"59","author":"C Hernandez","year":"2008","unstructured":"Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK (2008) Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 59:363\u2013380, quiz 382\u2013364","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR141","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","volume":"2","author":"JL Flynn","year":"1995","unstructured":"Flynn JL et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561\u2013572","journal-title":"Immunity"},{"key":"8301_CR142","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.4049\/jimmunol.157.11.5022","volume":"157","author":"G Senaldi","year":"1996","unstructured":"Senaldi G et al (1996) Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette\u2013Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 157:5022\u20135026","journal-title":"J Immunol"},{"key":"8301_CR143","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","volume":"56","author":"V Kindler","year":"1989","unstructured":"Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731\u2013740","journal-title":"Cell"},{"key":"8301_CR144","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"8301_CR145","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122\u20132127","journal-title":"Arthritis Rheum"},{"key":"8301_CR146","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522\u2013528","journal-title":"Ann Rheum Dis"},{"key":"8301_CR147","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.idc.2011.08.002","volume":"25","author":"RS Wallis","year":"2011","unstructured":"Wallis RS (2011) Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin North Am 25:895\u2013910","journal-title":"Infect Dis Clin North Am"},{"key":"8301_CR148","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","volume":"59","author":"SD Doherty","year":"2008","unstructured":"Doherty SD et al (2008) National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 59:209\u2013217","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR149","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000222431","volume":"219","author":"G Tsiouri","year":"2009","unstructured":"Tsiouri G et al (2009) Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis. Dermatology 219:119\u2013125","journal-title":"Dermatology"},{"key":"8301_CR150","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jaad.2008.12.024","volume":"60","author":"AJ Brown","year":"2009","unstructured":"Brown AJ, Lesher JL Jr (2009) Anti-tumor necrosis factor therapy and interpreting tuberculin skin tests. J Am Acad Dermatol 60:e21\u2013e22","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR151","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3899\/jrheum.090268","volume":"36","author":"N Inanc","year":"2009","unstructured":"Inanc N et al (2009) Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 36:2675\u20132681","journal-title":"J Rheumatol"},{"key":"8301_CR152","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00296-009-1027-z","volume":"30","author":"MN Tamborenea","year":"2010","unstructured":"Tamborenea MN, Tate G, Mysler E, Debonis J, Schijedman A (2010) Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int 30:613\u2013616","journal-title":"Rheumatol Int"},{"key":"8301_CR153","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","volume":"67","author":"G Matulis","year":"2008","unstructured":"Matulis G, Juni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67:84\u201390","journal-title":"Ann Rheum Dis"},{"key":"8301_CR154","first-page":"1427","volume":"13","author":"O Shovman","year":"2009","unstructured":"Shovman O et al (2009) QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuber Lung Dis 13:1427\u20131432","journal-title":"Int J Tuber Lung Dis"},{"key":"8301_CR155","doi-asserted-by":"crossref","unstructured":"Chiu HY, Hsueh PR, Tsai TF (2011) Clinical experience of QuantiFERON((R))-TB gold testing in psoriasis patients treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 164:553\u2013559","DOI":"10.1111\/j.1365-2133.2010.10137.x"},{"key":"8301_CR156","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","volume":"37","author":"R Diel","year":"2011","unstructured":"Diel R et al (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37:88\u201399","journal-title":"Eur Respir J"},{"key":"8301_CR157","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1183\/09031936.00114810","volume":"37","author":"M Sester","year":"2011","unstructured":"Sester M et al (2011) Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 37:100\u2013111","journal-title":"Eur Respir J"},{"key":"8301_CR158","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar1994","volume":"8","author":"H Hamdi","year":"2006","unstructured":"Hamdi H et al (2006) Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114","journal-title":"Arthritis Res Ther"},{"key":"8301_CR159","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.5588\/ijtld.10.0650","volume":"15","author":"P Weinfurter","year":"2011","unstructured":"Weinfurter P et al (2011) Predictors of discordant tuberculin skin test and QuantiFERON(R)-TB Gold In-Tube results in various high-risk groups. Int J Tuber Lung Dis 15:1056\u20131061","journal-title":"Int J Tuber Lung Dis"},{"key":"8301_CR160","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766\u20131772","journal-title":"Arthritis Rheum"},{"key":"8301_CR161","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.21382","volume":"52","author":"KL Winthrop","year":"2005","unstructured":"Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF (2005) Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 52:2968\u20132974","journal-title":"Arthritis Rheum"},{"key":"8301_CR162","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/ard.62.8.791","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62:791","journal-title":"Ann Rheum Dis"},{"key":"8301_CR163","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM200202213460815","volume":"346","author":"WS Lim","year":"2002","unstructured":"Lim WS, Powell RJ, Johnston ID (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623\u2013626","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"8301_CR164","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1529-8019.2009.01278.x","volume":"23","author":"A Gori","year":"2010","unstructured":"Gori A, Fabroni C, Prignano F, Lotti T (2010) Unusual presentation of tuberculosis in an infliximab-treated patient\u2014which is the correct TB screening before starting a biologic? Dermatol Ther 23(Suppl 1):S1\u2013S3","journal-title":"Dermatol Ther"},{"issue":"Suppl 1","key":"8301_CR165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/1153421-S0-000000000-00000","volume":"11","author":"R Huo","year":"2010","unstructured":"Huo R, Romanelli P (2010) Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis. Am J Clin Dermatol 11(Suppl 1):39\u201340","journal-title":"Am J Clin Dermatol"},{"key":"8301_CR166","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","volume":"56","author":"S Vermeire","year":"2007","unstructured":"Vermeire S et al (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease. Gut 56:1226\u20131231","journal-title":"Gut"},{"key":"8301_CR167","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM et al (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"key":"8301_CR168","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2230.2001.00753.x","volume":"26","author":"B Kirby","year":"2001","unstructured":"Kirby B, Marsland AM, Carmichael AJ, Griffiths CE (2001) Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 26:27\u201329","journal-title":"Clin Exp Dermatol"},{"key":"8301_CR169","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/j.jaad.2004.12.024","volume":"53","author":"W Myers","year":"2005","unstructured":"Myers W, Christiansen L, Gottlieb AB (2005) Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 53:S127\u2013S129","journal-title":"J Am Acad Dermatol"},{"key":"8301_CR170","first-page":"178","volume":"78","author":"TA Prossick","year":"2006","unstructured":"Prossick TA, Belsito DV (2006) Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis 78:178\u2013180","journal-title":"Cutis"},{"key":"8301_CR171","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/09546630701364776","volume":"19","author":"D Carr","year":"2008","unstructured":"Carr D et al (2008) Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatol Treat 19:97\u2013100","journal-title":"J Dermatol Treat"},{"key":"8301_CR172","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/0019-5154.62754","volume":"55","author":"RK Sivamani","year":"2010","unstructured":"Sivamani RK et al (2010) Biological therapy of psoriasis. Indian J Dermatol 55:161\u2013170","journal-title":"Indian J Dermatol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-012-8301-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-012-8301-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-012-8301-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:03:27Z","timestamp":1713485007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-012-8301-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,5]]},"references-count":172,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["8301"],"URL":"https:\/\/doi.org\/10.1007\/s12016-012-8301-7","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,5]]}}}